Welcome to our dedicated page for China Pharma news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma stock.
China Pharma Holdings, Inc. (NYSE American: CPHI) generates news across pharmaceuticals, medical devices, financing, and corporate actions. As a specialty pharmaceutical company focused on cardiovascular, CNS, infectious, and digestive diseases in China, its announcements often relate to product development milestones, regulatory progress, and changes in its capital structure.
News updates have covered the company’s reverse stock splits, including 1-for-10 and 1-for-5 ratios, as well as stockholder authorization for a potential reverse split of up to 1:20. These items are relevant for investors tracking share structure and listing status on the NYSE American. Company press releases also describe financing arrangements such as a Convertible Promissory Note and an at-the-market equity offering under a shelf registration statement on Form S-3.
Operational and product-related news includes the launch of an N95 medical protective mask, the listing of several drugs in the Catalogue of Medicines for People Infected with COVID-19, and regulatory milestones for key products. For example, the company has reported that its candesartan hypertension product passed the quality and efficacy consistency evaluation of generic drugs by the National Medical Products Administration of China. It has also provided updates on its Dry Eye Disease therapeutic device, including completion of third-party testing and expectations around market launch applications.
In addition, China Pharma issues news on technology transfer agreements for patented pharmaceutical inventions, such as ipragliflozin tablets and captopril microcapsules, where consideration is paid in restricted shares of common stock. Readers of the CPHI news page can review these developments to follow how the company manages its product pipeline, regulatory interactions, financing strategies, and corporate governance decisions over time.
China Pharma Holdings (NYSE American: CPHI) has announced a 1-for-10 reverse stock split effective April 15, 2025. The company's Board of Directors authorized a reverse split ratio between 1:10 and 1:20 on October 22, 2024, which was approved by stockholders on December 22, 2024. The Board ultimately fixed the ratio at 1:10 on March 26, 2025.
Under this arrangement, every 10 shares of CPHI's issued and outstanding common stock will be automatically converted into one share. The stock will continue trading on NYSE American under the symbol 'CPHI' with a new CUSIP number: 16941T 401. Any fractional shares resulting from the split will be rounded up to the next whole number, ensuring that stockholders' percentage interests remain unchanged except for minor adjustments due to fractional share treatment.
China Pharma Holdings (NYSE American: CPHI) has announced the successful completion of all redemptions under its Convertible Promissory Note agreement with Streeterville Capital, as of December 11, 2024. The note, originally issued on November 17, 2021, had a principal amount of $5,250,000 and was later amended to extend its maturity date to August 19, 2025.
CEO and Chairwoman Zhilin Li emphasized that this milestone strengthens the company's financial foundation. The completion of these redemptions positions the company to pursue its growth objectives and continue developing innovative pharmaceutical solutions for the Chinese healthcare market.
China Pharma Holdings (NYSE American: CPHI) has announced an at-the-market equity offering through a Securities Purchase Agreement dated December 12, 2024. The company may sell up to $600,000 worth of common stock through December 31, 2024. The pricing will be determined by the lower of the previous day's closing price or the 5-day average closing price, with a minimum price of $0.15 per share.
The offering is made under a shelf registration statement that became effective on February 6, 2024. The timing and number of shares sold will depend on various factors determined by the investor, with no guarantee that the company will be able to sell any shares.
China Pharma Holdings, Inc. (NYSE American: CPHI) has announced plans to launch its Dry Eye Disease Therapeutic Device in China by Q1 2025. The device, developed by its subsidiary Hainan Helpson Medical and Biotechnology Co., , is a patented medical treatment for dry eye disease. With 400 million dry eye disease patients in China, the market is projected to reach $579.51 million by 2030, growing at a CAGR of 6.04% from 2023-2030.
The device uses ophthalmic oxygen-enriched atomization technology to spray tiny oxygen-rich droplets into the eyes, improving moisture, oxygen supply, and tear fluid quality. This physical therapy approach aims to avoid drug-related side effects while providing more direct and comfortable treatment.
China Pharma Holdings Inc. (NYSE American: CPHI) announced a 1-for-10 reverse stock split effective March 6, 2023. This decision was approved unanimously by the Board of Directors and stockholders at the Annual Meeting held on December 27, 2022. Following the split, the new CUSIP number for common stock will be 16941T-203. Each stockholder's percentage interest will remain unchanged, although fractional shares will be rounded up to the nearest whole share. China Pharma specializes in pharmaceuticals targeting high-incidence diseases in China, and maintains a broad distribution network across the country.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced the launch of the N95 medical protective mask on December 26, 2022, following the issuance of a Registration Certificate by the Hainan Medical Products Administration. As COVID-19 cases surge in China, the demand for high-level medical protective masks has skyrocketed, leading to significant shortages in availability. CEO Li Zhilin highlighted the company's swift response to expand product lines for public health. This strategic move aims to optimize production capacities and ensure a stable supply of essential medical materials amidst the ongoing pandemic.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 on December 12, 2022. This follows China's end of strict COVID-19 policies, increasing public demand for related medications. Key products listed include the anti-viral Andrographolide and cold medicine Pusen OK. Additionally, recent regulatory changes will boost sales of roxithromycin and cefaclor. The company anticipates rising demand for health-related products amid the ongoing epidemic.
FAQ
What is the current stock price of China Pharma (CPHI)?
What is the market cap of China Pharma (CPHI)?
